REVIEW

Cannabinoid treatment of opiate addiction

Erin McLemon\(^1\) and Rose Chesworth\(^1,\)*

\(^1\)School of Medicine, Western Sydney University, Campbelltown NSW 2560, Australia

* r.chesworth@westernsydney.edu.au

Abstract

Opioid abuse is a growing global problem. Current therapies for opioid abuse target withdrawal symptoms and have several adverse side effects. There are no treatments to address opioid–induced neural adaptations associated with abuse and addiction. Preclinical research demonstrates interactions between the endogenous opioid and cannabinoid systems, suggesting that cannabinoids may be used to treat opioid addiction and dependence. The aim of this review is to assess how cannabinoids affect behavioural and molecular measures of opioid dependence and addiction–like behaviour in animal models. It appears that cannabidiol and cannabinoid receptor 1 (CB1R) antagonists have potential for treating drug-craving and drug-seeking behaviour, based on evidence from preclinical animal models. Ligands which inhibit the action of cannabinoid degradation enzymes also show promise in reducing opioid withdrawal symptoms and opioid self-administration in rodents. Agonists of CB1R could be useful for treating symptoms of opioid withdrawal; however, the clinical utility of these drugs is limited by side effects, the potential for cannabinoid addiction and an increase in opiate tolerance induced by cannabinoid consumption. The mechanisms by which cannabinoids reduce opioid addiction–relevant behaviours include modulation of cannabinoid, serotonin, and dopamine receptors, as well as signalling cascades involving ERK–CREB–BDNF and peroxisome proliferator–activated receptor–\(\alpha\). Identifying the receptors involved and their mechanism of action remains a critical area of future research.

Key words: Drug addiction; Mouse models; Behaviour; Opioid; Cannabinoid

Introduction

There has been a growing trend of opioid dependence and abuse in Australia [1], and globally there were an estimated 26.8 million people with opioid abuse disorder in 2016 [2]. Long-term opioid use is associated with opioid tolerance and toxicity, as well as sleep disorders, endocrinopathies and cognitive impairment [3]. Withdrawal from opioid dependence can induce symptoms such as increased heart rate, blood pressure, perspiration, fluctuating body temperature as well as joint and muscle aches [4]. Long-term management of opioid dependence largely depends on replacement therapy with the opioid agonists such as buprenorphine or methadone [5]. These replacement therapies can reduce withdrawal and relapse [6]. However, treatment with opioid agonists can have similar side effects to long-term opioid use [7, 8], and these agonists do not alter neural adaptations which increase relapse propensity (e.g. altered activity of dopaminergic VTA neurons in response to morphine [9, 10]). Thus, there is an urgency to uncover other strategies to manage opioid dependence and addiction.

Clinical evidence suggests cannabinoids, which are compounds found in the Cannabis sativa plant that bind to endogenous cannabinoid receptors, may present an effective therapeutic option for managing opioid addiction. Some individuals who use cannabis while undergoing opioid withdrawal perceive an alleviation of some opioid withdrawal symptoms [11], and there is a negative correlation between reported cannabis use and injected opioid drug use (i.e. increased cannabis use corresponds with decreased opioid use) [12]. Supporting this, some American states have reported decreased opioid use after cannabis legalisation [13]. These results are perhaps not surprising, considering well-established interactions between the endogenous opioid and the endogenous cannabinoid (endocannabinoid) systems, with both systems being involved in pain relief, and opioid and cannabinoid receptors are expressed in neural pathways and brain regions associated with addiction [14–17].

In this narrative mini-review we will examine the therapeutic potential of cannabinoids for opioid dependence and addiction–like behaviour, using data from preclinical animal models. We will first outline the endogenous opioid and endocannabinoid systems as well as interactions between them. We will then detail reductions in addiction–like behaviour by cannabinoid compounds in animal models of opioid addiction–relevant behaviour, and in clinical trials, where this data is available.
The Endogenous Opioid System

The endogenous opioid system is composed of receptors and peptide chains found in the central, peripheral, and enteric nervous systems. The endogenous opioid peptides are β-endorphin, met-enkephalin, dynorphin, and neuropeptide-Y [18]. There are also three identified precursors to these peptides: proopiomelanocortin, proenkephalin, and prodynorphin [18]. Opioid receptors, μ- (MOR), δ- (DOR) and κ- (KOR) are G-protein coupled receptors that inhibit adenyl cyclase activity, block calcium channels, and activate potassium channels [19]. Importantly, opioid receptors are highly expressed in brain regions associated with reward (see Table 1 for definitions), including the ventral tegmental area (VTA), nucleus accumbens (NAc), hypothalamus and amygdala [17]. Opioid reward, tolerance and relapse-like behaviour are associated with MOR activation [20–22], while DOR appear involved in the maintenance of opioid reward and dysphoric aspects of opioids, including depression and anxiety [21–23]. KOR modulates drug consumption as well as anxiety and depressive-like behaviours [21, 22]. MOR can mediate glutamatergic activity in the NAc and chronic MOR activation can lead to glutamate dysfunction (e.g. decreased GluR1 surface expression following chronic morphine) [24]. Importantly, glutamate dysfunction is associated with the development of compulsive behaviour for abused drugs and plays a significant role in substance use disorder [25], providing a potential mechanism for how MOR activation can result in addiction-relevant behaviour.

The Endocannabinoid System

The endocannabinoid system is composed of endogenous receptors (e.g. cannabimimetic receptor 1 and 2, CB1R and CB2R respectively), ligands [e.g. 2-arachidonoylglycerol (2-AG) and N-arachidonoylthanolamine (anandamide)] and enzymes for the synthesis and degradation of cannabinoid compounds (e.g. fatty acid amide hydrolase (FAAH), diacylglycerol lipase alpha (DAGLα), monoacylglycerol lipase (MAGL), and α/β-hydrolase domain-containing 6 (ABHD6)) [26, 27]. In the central nervous system, CB1R are predominantly expressed on neuronal terminals, and are more highly expressed than CB2R, which are expressed on dopamine neurons in the VTA [28]. Like opioid receptors, CB1R is a G-protein coupled receptor, and regulates activity of cyclic adenosine monophosphate (cAMP), dopamine, γ-aminobutyric acid (GABA) and glutamate [29]. CB1R is highly expressed in regions of the brain associated with reward and learning, with high levels of receptor expression in the cortex, striatum, hippocampus, thalamus, hypothalamus, substantia nigra pars reticulata and cerebellum [30, 31]. The endocannabinoid system alters plasticity in brain areas responsible for emotional responses and memory formation, modulating hippocampal synaptic strength, regulating VTA-NAc pathways and reducing glutamatergic activity in the dorsal and ventral striatum [32]. Considering both the endogenous opioid and endocannabinoid systems are involved in processes associated with addiction, it is necessary to consider how these systems interact.

Endogenous opioid and endocannabinoid interactions

The endogenous opioid and endocannabinoid systems interact anatomically and functionally. Anatomically, there is an overlap in the distribution of MOR and CB1R in the limbic system [17, 19]. Agonists for both receptors produce antinociception, sedation, hypotension, motor depression and mediate signalling pathways associated with drug tolerance, dependence and substance use disorder [14].

<table>
<thead>
<tr>
<th>Technical Terms</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acquisition</td>
<td>Initial learning of drug reward associations or drug reinforcement behaviours</td>
</tr>
<tr>
<td>Aversion</td>
<td>Dislike of a drug/drink cues/drug context; evidenced by staying away from a drug-associated context or cessation of drug self-administration</td>
</tr>
<tr>
<td>Cannabinoids</td>
<td>Compounds from the Cannabis Sativa plant which bind to endogenous cannabinoid receptors</td>
</tr>
<tr>
<td>Extinction</td>
<td>Cessation of drug-taking behaviours and/or decreased strength of drug-cue/context associations</td>
</tr>
<tr>
<td>Opioids</td>
<td>Substances that act on opioid receptors, and can produce effects such as pain relief and reward</td>
</tr>
<tr>
<td>Psychoactive</td>
<td>A chemical substance that changes nervous system function and results in alterations in perception, mood, consciousness, cognition, or behaviour</td>
</tr>
<tr>
<td>Reward</td>
<td>An experience which is subjectively pleasurable. In preclinical models, reward refers to associations between an unconditioned stimulus, for example a drug, and a discrete cue/context</td>
</tr>
<tr>
<td>Reinforcement</td>
<td>Strengthening the stimulus–response relationship between a behaviour and drug</td>
</tr>
<tr>
<td>Reinstatement</td>
<td>Drug cues, stress or a low dose drug prime can cause the return of drug–seeking behaviours or approach of a drug–associated environment</td>
</tr>
<tr>
<td>Self-administration</td>
<td>Behavioural paradigm in rodents, where animals learn to infuse or consume drugs of abuse via an operant response e.g. nose poke, lever press</td>
</tr>
<tr>
<td>Withdrawal</td>
<td>Physiological effects following cessation of drug use</td>
</tr>
</tbody>
</table>

Cannabinoid treatment can influence endogenous opioid signalling and function. Acute exposure to CB1R agonists, Δ⁹-tetrahydrocannabinol (THC) and CP55,940, increases the activity of endogenous opioid peptides [33, 34], while chronic exposure to the CB1R agonists THC, R-methanandamide (AM356) and CP55,940 increases levels of endogenous opioid precursors (e.g. dynorphin B) [33]. Chronic exposure to CB1R agonists can cause cellular tolerance to opioids and desensitisation of MOR [35]. CB1R agonists can increase the antinociceptive effects of opioids, by several mechanisms including increasing the release of the endogenous opioid dynorphin A [36]. Cannabinoids such as THC and cannabidiol (CBD) can allosterically modulate MOR and DOR, altering the ability of opioid ligands to bind to and remain at the binding site [37]. FAAH inhibitors, in conjunction with anandamide, produce antinociceptive effects via CB1R and KOR [38]. This data indicates several cannabimimetic agonists and enzyme inhibitors can modulate opioid receptor signalling and binding.

These interactions are reciprocal, with opioids affecting the function of the endocannabinoid system. Activation of opioid receptors can cause tolerance and downregulation of cannabinoid receptors [16]. Acute morphine administration reduces the expression of CB1R in the dorsal caudate putamen, NAc and septum; however, chronic morphine increases CB1R expression in the caudate putamen, cortex and midbrain [39, 40]. In addition, MOR and KOR can mediate rewarding properties of cannabinoids, with MOR
being necessary for THC reward in conditioned place preference (CPP) [41]. Naloxone, a MOR antagonist, can induce cannabinoid withdrawal symptoms and inhibit the self-administration of CB1R agonists WIN55,212-2 and HU-210 in rats [39], suggesting naloxone can partially substitute for CB1R antagonists. MOR and DOR double knock out mice display decreased THC-induced hypothermia, slower development of tolerance and reduced expression of withdrawal to THC [42], indicating MOR and DOR act together to modulate addiction-relevant behaviour for THC. These studies suggest the endogenous opioid and endocannabinoid systems interact to regulate addiction-relevant behavioural and neural processes.

**Effects of cannabinoids on opioid withdrawal, dependence and addiction-like behaviour: Δ⁹-tetrahydrocannabinol (THC)**

THC is the major psychoactive cannabinoid found in cannabis sativa and primarily mediates its psychoactive effects through CB1R, of which it is a partial agonist [43]. THC also allosterically modulates MOR [37].

Initial investigations into THC as a treatment for opioid dependence focused on its effects on opioid withdrawal (see Figure 1 for brief methods). THC attenuates naloxone-induced withdrawal symptoms in rats [44-46], without inducing morphine withdrawal itself [44], initially suggesting THC could be useful in preventing morphine withdrawal. Overall, THC reduces the intensity of some morphine withdrawal symptoms, including defecation and diarrhoea but not wet dog shakes and ear blanching [44]. THC treatment also increases the dose of naloxone required to induce morphine withdrawal [45, 47], suggesting protection from naloxone-precipitated morphine withdrawal by THC and potential activation of MOR by THC. Similar effects on naloxone-precipitated withdrawal are reported for THC analogues, such as Δ⁹-tetrahydrocannabinol and 11-hydroxy-Δ⁹-tetrahydrocannabinol [47-49]. These early studies suggested that THC or THC-induced mechanisms could be relevant in treating opioid withdrawal. Early clinical studies appeared to support this hypothesis. A reduction in opioid withdrawal by the synthetic THC stereoisomer dronabinol was reported in humans [50, 51]. An initial study showed that 30 mg of dronabinol reduced opioid withdrawal symptoms during an early detoxification period before administration of the extended release MOR antagonist naltrexone [50]. There were no differences between the dronabinol and the control group in retention and medication compliance following initial detoxification [50]. Interestingly, patients in this study who smoked marijuana were more likely to remain in treatment and had less difficulty with insomnia and anxiety, irrespective of dronabinol treatment, suggesting therapeutic utility of marijuana and possibly THC in withdrawal symptom management [50]. Similarly, 20 and 30 mg dronabinol can supress opiate withdrawal symptoms in opioid-dependent patients [51]. Despite promising effects of dronabinol in reducing initial opioid withdrawal, doses of dronabinol over 20 mg during opioid withdrawal can increase the risk of tachycardia, sedation and perceived drug high, raising safety concerns about its use and limiting the potential of dronabinol in clinical settings [51, 52]. These later clinical studies indicate that despite initial promise, THC does not appear a viable treatment for opioid withdrawal.

However, THC could be used to treat other aspects of opioid addiction. Some studies indicate that acute THC can reduce the rewarding effects of opiate (i.e. eliciting approach behaviour, such as in conditioned place preference [53]; see Figure 2 for brief methods) and reinforcing effects of opiates (i.e. strengthening the stimulus-response relationship between a behaviour and drug infusion, such as in self-administration [53], see Figure 3 for brief methods). In a self-administration paradigm in rhesus monkeys, acute and repeated THC dose dependently reduces heroin self-administration, suggesting a reduction in heroin reinforcement when THC is present [54, 55]. Similarly, in Sprague–Dawley rats, THC also reduces fixed ratio operant responding for heroin [56],

**Figure 1. Components of the addiction cycle as modelled in rodents using opiate withdrawal. The addiction cycle, described by Piazza and Deroche–Gamonet [139], includes A) sustained drug use (at least 5 days via mini-pump or repeated injections), B) spontaneous withdrawal in home cage or novel environment or C) opiate-induced withdrawal. Withdrawal symptoms are assessed by a trained observer in D).**
suggesting THC can reduce the reinforcing properties of heroin. However, some studies show opposite effects, indicating THC can increase opiate reward and reinforcement. One study demonstrated that low dose THC can increase motivation for heroin on a progressive ratio schedule in Sprague-Dawley rats, but this effect was only evident when response requirements for heroin were low [56], and the THC dose used in this study was lower than that used in fixed ratio studies. Recently, it was shown that ventral hippocampal THC infusions can increase reward for subthreshold morphine in a place preference paradigm in rats [57]. In this experiment, THC increased frequency and bursting rates of VTA dopaminergic neurons, which may account for the increase in the rewarding properties of THC combined with subthreshold morphine [57]. Earlier research did not identify a neural locus of effect when demonstrating that systemic THC can reduce opiate reward and reinforcement (e.g. [54–56]), and it is possible that the site where THC acts in the brain can modulate whether THC enhances or impedes opiate reward. Overall, systemic THC appears to reduce opiate reinforcement, but there may also be dose- and location-dependent effects of THC on opiate-induced reinforcement.

Despite this, THC does not appear to strongly modulate opiate extinction or reinstatement. Low dose THC does not restate heroin-seeking behaviour in rats, in the absence of heroin cues, a heroin prime or a stressor [58]. Similarly, in rhesus monkeys, daily THC does not affect extinction of heroin-seeking or resumption of heroin self-administration after extinction [55]. While there is limited preclinical research on this topic, the data available suggests THC affects opiate reward and reinforcement, but not extinction and reinstatement processes.

Adolescent cannabis use is associated with increased susceptibility for developing later substance use disorder [59], and understanding the persistent effects of THC exposure in adolescence may help explain the involvement of prior cannabinoid use on opioid addiction. Despite adult THC treatment mostly reducing heroin use in rodents, adolescent THC exposure appears to increase susceptibility to addiction-like behaviour and brain changes in adulthood. Chronic adolescent THC treatment increases heroin self-administration in adult rats at moderate heroin doses (i.e. 50 – 85 μg/kg/infusion [60, 61]), but not low heroin doses (i.e. 20 μg/kg/infusion [62]). Adolescent THC increases preproenkephalin mRNA expression and MOR guanosine triphosphate-coupling in the NAc shell in adulthood [60], and MOR function in the NAc shell is correlated with heroin intake [60]. Adolescent THC exposure also increases stress-induced reinstatement for heroin in adult rats [62], suggesting adolescent THC can increase opiate relapse propensity. Strain dependent effects of adolescent THC have also been reported: In Lewis rats, a strain that more readily acquires psychostimulant and opiate self-administration than other outbred rat strains such as Fisher 344 rats [63], adolescent THC has no effect on acquisition of heroin CPP, but potentiates heroin-primed reinstatement of CPP, and increases self-administration and motivation for heroin [64, 65].
However, in Fischer 344 rats, a strain that displays resistance to opiate self-administration [63], THC exposure increases heroin CPP and increases cue-induced reinstatement of heroin-seeking, but has no effect on self-administration and motivation for heroin [64, 65]. This suggests that THC can increase susceptibility to opiate abuse-like behaviours, irrespective of genetic susceptibility or resistance to opiate self-administration. Together, this data suggests adolescent THC treatment can increase susceptibility to adult heroin addiction-like behaviour.

Despite this, opposing effects have been reported for the highly selective MOR agonist oxycodone, whereby chronic adolescent THC can reduce oxycodone self-administration in adult rats in a dose dependent manner [66, 67]. These effects are observed only under extended access conditions, and are blocked by administration of the CB1R antagonist SIR14176 [66, 67], suggesting the decreased susceptibility to oxycodone by THC is mediated by CB1R. The reasons for different effects of adolescent THC on subsequent heroin and oxycodone administration are yet to be resolved, but may result from methodological differences (e.g. extended access conditions [67]) and pharmacokinetic differences between heroin and oxycodone (e.g. heroin has a higher affinity for the MOR than oxycodone).

In conclusion, while adolescent THC appears to increase subsequent opioid susceptibility, THC treatment in adulthood can reduce the rewarding and reinforcing effects of opioids. This effect may be mediated through THC-induced activation of CB1R [67]. While the side effect profile and abuse potential of THC can limit its application in the clinic, understanding THC’s mechanisms of action in reducing opioid reward could lead to the development of novel compounds targeting these mechanisms. Further research into the receptors and/or proteins THC acts on alter opiate addiction-relevant behaviours is strongly warranted.

CB1R agonists

Considering the reduction in opioid withdrawal by THC appears mediated by CB1R, other CB1R agonists have been investigated for their potential to limit opioid withdrawal and addiction-like behaviours. Administration of CB1R agonists can reduce opioid withdrawal symptoms. The CB1R agonist WIN 55,212-2 decreases the intensity of morphine withdrawal-induced contractions in guinea-pig ileum cells [68]. Smooth muscle activity, as seen in the ileum, is associated with opioid-induced constipation and withdrawal-associated diarrhea [4]. Administration of the endogenous CB1R agonist 2-AG or the CB1R agonist HU-210 reduces naloxone-precipitated morphine withdrawal in morphine-dependent mice [49]. This is consistent with studies showing THC, a partial CB1R agonist, attenuates opioid withdrawal symptoms [44-46] and further supports the theory that opioid withdrawal may be mediated by CB1R.

While CB1R agonists appear to reduce opioid withdrawal symptoms, several studies indicate they can also increase the abuse potential of opiates. Systemic [69] and intra-basolateral amygdala [70] WIN 55,212-2 administration increases morphine reward in mice and rats, and this effect is dependent on CB1R, as it is blocked by co-administration of CB1R antagonist SIR14176A [69]. In rats, chronic pretreatment with the CB1R agonist CP 55,940 increases subsequent morphine self-administration and locomotor sensitization [71], while acute WIN 55,212-2 increases heroin self-administration in Sprague-Dawley rats [72]. In monkeys self-administering heroin, CP 55,940 and WIN 55,212-2 reduce heroin self-administration [73]. However, the doses used in this study also decrease responding for a food reinforcer [73], which may suggest CP 55,940 and WIN 55,212-2 reduce locomotor activity in general, and confound the interpretation that these agonists limit heroin self-administration. These results indicate that CB1R agonists often increase opioid reward.

It seems enhancing effects of CB1R agonists on opiate reward and reinforcement can be dose-dependent. Co-administration of maximally reinforcing doses of CP 55,940 and heroin decreases lever responding for the combination of both drugs, suggesting CP55,940 can substitute for heroin [74]. Similarly, in a place preference paradigm, CP 55,940 treatment during acquisition of heroin CPP does not enhance the rewarding effects of heroin, yet the doses of CP 55,940 and heroin in this study already were rewarding in CPP, suggesting cannabinoid agonists can enhance opioid reward when subthreshold doses are used [75]. Indeed, this interpretation was recently confirmed – WIN 55,212-2 combined with subthreshold morphine dose-dependently causes a conditioned place aversion (CPA), while supra-threshold doses of morphine combined with WIN 55,212-2 shift morphine CPP to a CPA [76]. Together, these studies suggest that CB1R agonists mostly increase opioid sensitivity and reward, limiting their suitability for opioid addiction treatment. However, there are indications that this increase in opioid reward is only evident in rodents (e.g. [73]), and further research on the interactions between CB1R and opioid reward in primates is warranted.

CB1R agonists can alter the reinstatement of opiate seeking, but whether CB1R agonists facilitate or inhibit reinstatement can depend on the brain region targeted. Systemic administration of HU-210, as well as CP 55,940 and WIN 55,212-2 reinstates drug-prized heroin-seeking in a self-administration paradigm in rats [58, 77]. However, when WIN 55,212-2 is administered directly into the NAc, it reduces drug-prized reinstatement of morphine CPP in rats [78], and this is associated with elevated NAC and VTA c-fos activation [79]. Discrepancies between systemic and intra-NAC CB1R agonist administration may arise due to the role of the NAc in reinstatement. WIN 55,212-2 prior to reinstatement inhibits glutamate inputs to the NAc [80], and glutamatergic activity in the NAc modulates opiate reinstatement [81, 82, 88]. It is possible that while CB1R activation in the NAc alone can reduce drug-prized reinstatement, systemic CB1R agonist administration may also affect other structures critical for reinstatement, for example CB1R on cortical glutamatergic afferents regulates dopamine release in the NAc and could increase reinstatement propensity [83]. Despite effects of WIN on reinstatement, intra-NAC WIN given during extinction does not affect extinction or reinstatement of morphine CPP [78], despite WIN increasing NAC neuronal activity when administered during extinction [80], and reducing the pCREB/CREB ratio in the NAc [79]. Thus, while CB1R agonists can modulate relapse-like behaviour for opiates, further research is required to clarify effects of CB1R agonists on extinction of opiates.

Cannabidiol (CBD)

CBD is a non-intoxicating cannabis constituent with several pharmacological mechanisms, including being a weak negative allosteric modulator of CB1R, a serotoninergic 5-HT1A receptor agonist, and a vanilloid TrpV1 agonist [84-88]. CBD can also allosterically modulate opioid receptors and accelerate MOR agonist dissociation from the binding site, thus reducing MOR activity [37]. CBD is associated with increased endocannabinoid activity by inhibition of FAAH and subsequent increased levels of anandamide by a reduction in the hydrolysis rate [89]. Preclinical research indicates a limited role for CBD in reducing opioid withdrawal symptoms. CBD can reduce naloxone-induced withdrawal symptoms [45], but is less effective than other cannabinoids in this effect, for example THC. THC produces a 3- to 6-fold increase in the effective dose of naloxone for precipitating withdrawal, whereas CBD only produces a 2-fold increase in the effective dose of naloxone [45]. CBD also has a limited effect on the expression of opiate withdrawal, modestly decreasing jumping behaviour, but no other behaviours, compared to vehicle controls [45]. While CBD combined with THC increases THC’s attenuation of morphine withdrawal,
Figure 3. Components of the addiction cycle as modelled in rodents using intravenous self-administration. The addiction cycle, described by Piazza and Deroche–Gamonet [139], includes A) recreational/sporadic drug use, B) escalation of use, C) extinction/abstinence, and D) relapse. These are modelled in rodents via A) self-administration, B) progressive ratio responding, C) extinction training or home cage abstinence, and D) reinstatement (stress/drug-primed/cue-induced).

However, there is some evidence suggesting CBD attenuates opiate reward. Co-administration of CBD with morphine dose-dependently increases the intracranial self-stimulation (ICSS) threshold in the medial forebrain bundle in rats, indicating a reduction in brain reward threshold [91]. CBD’s reduction in morphine-induced ICSS was reversed by pretreatment with the serotonergic (5-HT) 1A receptor antagonist and potent dopamine D4 receptor (D4R) agonist, WAY-100635, indicating CBD mediates morphine reward via stimulation of 5-HT1A or inhibition of D4R [91]. CBD alone also dose-dependently reduces brain reward thresholds [91]. While infusions of CBD alone into the ventral hippocampus do not affect subthreshold morphine CPP, infusions of CBD in the ventral hippocampus reverse THC’s enhancement of subthreshold morphine reward, and these effects are mediated by modulation of extracellular signal-regulated kinase (ERK) phosphorylation [57]. This suggests CBD may reduce THC’s enhancement of morphine reward via ERK signalling in the ventral hippocampus [57]. These results indicate that CBD can reduce the rewarding effects of opioids, and these effects can be mediated by 5-HT1A and/or D4 receptors.

CBD may also reduce addiction-relevant behaviour via persistent effects on opiate memory. While CBD does not reduce heroin self-administration or extinction of heroin self-administration in rats, it can reduce cue-induced heroin reinstatement [92]. Effects of CBD on cue-induced reinstatement are persistent, lasting for 2 weeks after CBD treatment, suggesting long-lasting effects of CBD on cue-associated cue memory [92]. Similarly, CBD interrupts reconsolidation of morphine CPP memory for up to 14 days after CBD treatment in a rat model, and this does not return upon drug- or stress-primed reinstatement following extinction, again indicating that CBD can impair drug-memory [93]. CBD prior to memory reactivation also suppresses naltrexone-precipitated...
place aversion in the CPP context [93], demonstrating that CBD can limit recall of a drug–associated environment. CBD treatment normalises heroin–induced upregulation of CB1R RNA and protein levels in the NAc core and shell, and downregulates GluR1 protein in the NAc core and shell [92], suggesting that CBD may ameliorate drug–induced neural adaptations. Together, this suggests CBD can impair opiate–based memory in rodents, potentially by interrupting reconsolidation, and this can occur via modulation of GluR1 and CB1R in the NAc. Recent clinical trials also suggest CBD can reduce opiate craving and the willingness to use opioids. In humans, CBD reduces heroin cue–induced craving and anxiety in heroin abstinent individuals [94]. This effect was observed 24 hr after a single CBD treatment, and persisted for one week following 3 days of CBD treatment [94]. CBD also reduced physiological measures of stress, such as heart rate and salivary cortisol levels, compared to placebo–treated controls, suggesting CBD may reduce physiological responses to stress in order to reduce cue–induced craving for heroin [94]. In addition, a prospective cohort study of patients with chronic pain on long-term opioid treatment demonstrated a trend for CBD treatment to increase willingness to cease opioid medication [95]. In this study, 50 of 94 participants reduced their opioid dose over the eight weeks, and patients indicated reluctance to cease opioid use due to perceived risk of refusal to renew new opioid treatment [95], suggesting that patients may have reduced their opiate use further if they were guaranteed future access to opiates if necessary. Together, this suggests CBD may reduce opiate craving and use in humans, but further research is required to confirm these conclusions.

**Cannabinoid enzyme inhibitors: FAAH inhibitors**

FAAH inhibitors limit the degradation of, and thus increase the concentration of the fatty amide family of lipid transmitters, including the most widely studied endocannabinoid, anandamide. It is hypothesised that FAAH inhibitors can increase anandamide availability, which elevates cannabinoid receptor stimulation and thus reduces the rewarding and relapse–inducing effects of abused drugs, including opiates [96].

FAAH inhibitors show potential in reducing opioid withdrawal. FAAH inhibitors, including URB–597 and PF–3845, reduce withdrawal symptoms in morphine–dependent mice and rats [46, 97, 98]. Recently, N–oleoylglycine (OGLy), a fatty acid amide which appears to act as a FAAH inhibitor and a peroxisome proliferator–activated receptor alpha (PPARα) agonist, limited naloxone–precipitated morphine withdrawal symptoms in male rats, including abdominal contractions, lying on belly, diarrhoea and mouthing movements [99]. The effects of OGLy on morphine withdrawal were mediated by CB1R and PPARα [99], indicating that increasing endogenous cannabinoid levels could be a potential treatment option for opioid dependence. Furthermore, monomethylated oleoyl glycine (HUS595), which has improved stability compared to oleoyl glycine and inhibits FAAH and activates PPARα in vitro, reduces somatic and aversive effects of naloxone–precipitated morphine withdrawal [100], again suggesting potential as a treatment for opioid withdrawal. Effects of HUS595 on morphine withdrawal were prevented by both a PPARα antagonist and a CB1R antagonist [100], indicating HUS595 may reduce naloxone–precipitated morphine withdrawal by increasing activity of PPARα and CB1R. HUS595 also does not produce rewarding or aversive effects on its own and does not modify locomotor activity, supporting its therapeutic utility [100]. Together, these studies demonstrate that FAAH inhibitors may act via increasing CB1R and PPARα signalling to limit opioid withdrawal behaviours in rodents.

Some, but not all FAAH inhibitors limit morphine withdrawal–induced place aversion. The FAAH inhibitor URB–597 facilitates extinction of naloxone–precipitated morphine withdrawal–induced conditioned aversion [101], but does not limit morphine–induced reinstatement of CPA [102]. This suggests URB–597 can facilitate extinction memory processes, which can be relevant to reducing morphine use. Similarly, OGLy has been shown to also block the aversive effects of morphine withdrawal in a place aversion paradigm [103], suggesting OGLy can reduce morphine withdrawal effects. However, the FAAH inhibitor PF–3845 does not limit morphine withdrawal–induced CPA [46], and URB597 and PF–3845 have no effect on the establishment or reinstatement of CPA [104]. Despite this, a combination of a low–dose MAGL inhibitor JZL184, and high dose FAAH inhibitor PF–3845, as well as a dual FAAH–MAGL inhibitor SA–57, reduces withdrawal symptoms in morphine–dependent mice [105], but does not prevent naloxone–precipitated withdrawal CPA in mice [46]. While some FAAH inhibitors appear effective in reducing morphine withdrawal–induced symptoms, it appears a dose–dependent combination of FAAH and MAGL inhibition may sometimes be required to reduce morphine withdrawal–induced CPA.

There is limited research into the effects of FAAH inhibitors on addiction–like behaviours for opiates. Administration of AM404, which inhibits anandamide reuptake, reduces motivation for heroin in a self–administration paradigm in rats [56]. Subthreshold doses of AM404 combined with the FAAH inhibitor URB–597 also reduce heroin motivation in a self–administration paradigm in rats [56]. While AM404 is self–administered by rhesus monkeys [106], it is not rewarding in a place preference paradigm in rats [107], and does not enhance BSR in rats [108]. Despite promising findings with AM404, administration of the FAAH inhibitor URB–597 does not promote extinction of morphine CPP, or limit subsequent drug–primed reinstatement of morphine CPP [101, 102]. Similarly, OGLy does not limit formation of morphine CPP or prevent reinstatement of morphine CPP [103], suggesting FAAH inhibitors may reduce motivation for, but not extinction or reinstate ment of opiates in rodents.

Clinical trials have started to examine if FAAH inhibitors may be relevant for opioid withdrawal symptoms and opioid self–administration. While a clinical trial for the FAAH inhibitor BIA10–2474 was discontinued due to severe side effects [109], a comprehensive review of safety information relevant to BIA10–2474 suggested other FAAH inhibitors do not pose similar safety risks [110], and interest in FAAH inhibitors has recently regained traction. Importantly, FAAH inhibitors such as URB–597 have low abuse liability as they do not induce place preference [111, 112], they are not spontaneously self–administered by subjects [113], and have a low toxicity profile [112]. This suggests FAAH inhibitors may have clinical utility in the management of opioid–abuse.

**Cannabinoid enzyme inhibitors: MAGL inhibitors**

Limited research suggests MAGL inhibitors can limit opioid withdrawal and addiction–like behaviours. MAGL inhibitors limit the hydrolysis of 2–AG, increasing endocannabinoid tone. The selective MAGL inhibitor JZL184, which increases levels of 2–AG but not anandamide, blocks naloxone–precipitated and also spontaneous opioid withdrawal symptoms in opioid–dependent mice [46, 97]. Despite this, JZL184 does not prevent naloxone–precipitated CPA in mice [46], suggesting JZL184 can limit withdrawal symptoms but not withdrawal–environment associations. A different MAGL inhibitor, MNN110 prevents acquisition of naloxone–induced withdrawal CPA in rats, when administered systemically or by direct infusion to the basolateral amygdala or the interoceptive insular cortex; the latter region is activated during opioid withdrawal [114]. The dual FAAH–MAGL inhibitor SA–57 reduces heroin self–administration and heroin–seeking in mice [115], suggesting a combined FAAH–MAGL inhibitor may limit relapse–like behaviour. Together, this suggests MAGL inhibition can limit opi-
oid withdrawal, as well as heroin self-administration and heroin-seeking. New therapeutic options may include combinations of MAGL and FAAH inhibition [115], particularly for the inhibition of opioid withdrawal.

**CB1R antagonists**

CB1R antagonists show potential for the treatment of opioid withdrawal. While acute administration of the CB1R antagonist SR141716A induces morphine withdrawal in morphine-dependent rats [116], chronic administration of the CB1R antagonist SR141716A reduces spontaneous morphine withdrawal symptoms, including wet shakes and jumping [117]. Despite this, there is no effect of acute SR141716A on naloxone-induced withdrawal [117]. CB1R knockout mice also express reduced withdrawal symptoms after naloxone administration [118], suggesting chronic, but not acute CB1R antagonism may be relevant for reducing morphine withdrawal.

Acute administration of the CB1R antagonists AM251, AM4113 and AM6527 inhibits morphine withdrawal-induced CPA in rats, but has no effect on the reinstatement of CPA [104]. Direct infusions of AM251 into the bed nucleus of the stria terminalis and the central amygdala reduces morphine withdrawal-induced CPA, suggesting a key role for these regions in morphine withdrawal CPA [119].

CB1R antagonists also show therapeutic potential for reducing opiate reward and relapse-like behaviour. Several studies indicate SR141716A significantly reduces opioid reinforcement: self-administration and motivation for heroin is significantly reduced in rats co-treated with SR141716A [39, 74, 77], while self-administration of morphine is blocked by SR141716A pretreatment in mice [91]. SR141716A pretreatment also inhibits acquisition of morphine CPP in mice [39, 69, 117], suggesting SR141716A can block morphine reward. SR141716A infusions into the NAc of rats during morphine withdrawal reduces preference for a morphine-associated environment [120], suggesting SR141716A can facilitate the loss of morphine-environment associations. SR141716A reduces drug-primed reinstatement of heroin and morphine [69, 77], even after an extended period of abstinence [15], indicating potential for reducing relapse-like behaviour. Effects of CB1R blockade on opiate reinstatement appear mediated by the NAc core and prefrontal cortex, as SR141716A infused into the NAc core and prefrontal cortex, but not the basolateral amygdala, attenuates cue-induced reinstatement of heroin-seeking [121]. However, chronic pretreatment with SR141716A does not reduce subsequent morphine-induced locomotor stimulation [71], and higher doses of SR141716A also induce place aversion in opiate-dependent mice and rats [39, 117], suggesting therapeutic effects of SR141716A occur within a specific dose range. Furthermore, while SR141716A does not exhibit rewarding properties in a place preference paradigm [117], it does increase brain stimulation reward thresholds [122] and reduces responding for food-predictive cues [123], suggesting it may have depressant-like effects or mood altering properties. Recently, due to side effects associated with SR141716A treatment in clinical trials (e.g. anxiety, depression, suicidal thoughts), investigations into other CB1R modulators have been conducted.

Recent investigations into other CB1R antagonists indicate therapeutic potential for opiate addiction-like behaviour. The CB1R antagonist AM251 impairs acquisition of morphine CPP in mice, indicating a reduction in morphine reward [124]. Also, the CB1R neutral antagonist AM4113 dose-dependently inhibits self-administration of intravenous heroin in rats, with no effect on brain stimulation reward thresholds [122], suggesting AM4113 can reduce heroin reinforcement. There are mixed reports on whether AM251 can enhance extinction of morphine CPP: one study demonstrated that systemic AM251 did not facilitate extinction of morphine CPP in rats [101]. However, intra-NAc AM251 reduces morphine CPP reinstatement following extinction [125], and infusions of AM251 into the dorsal hippocampus, but not the prefrontal cortex, inhibits drug-primed reinstatement of morphine CPP [126]; suggesting AM251 can limit reinstatement of morphine-seeking, even if AM251 does not affect extinction. AM251 treatment prior to reinstatement blocks the morphine-induced upregulation of CB1R in the NAc and the hippocampus, and reduces activation of the ERK-CREB-BDNF cascade in the NAc and hippocampus [79, 124]. Considering the involvement of ERK, CREB and BDNF in neural plasticity, which is critical for drug-associated learning [127, 128], and how CB1Rs bind to Gαi, G-proteins to activate ERK, it is possible CB1R mediates opiate reinstatement via this cascade.

Interestingly, AM251 can also have synergistic effects with morphine. Subchronic intra-NAc AM251 in conjunction with subthreshold morphine produces morphine place preference [129]. AM251 appears to act at the basolateral amygdala and the prelimbic cortex to mediate these synergistic effects with morphine [76, 130]. Effects of AM251 in the prelimbic cortex are blocked by systemic administration of the broad-spectrum dopamine receptor antagonist α-flupenthixol, suggesting that CB1R in the prefrontal cortex can mediate a motivational valence switching mechanism which modulates dopaminergic transmission and alters reward value [130]. Synergistic effects between AM251 and opiates, and the potential limitations this could present for the therapeutic utility of CB1R antagonists, requires further investigation.

**CB2R agonists**

Recent research suggests some CB2R agonists can limit opiate addiction-relevant behaviour. Pretreatment with CB2R agonists e.g. AM1710, AM1241 and LY2828360 reduces naloxone-precipitated opioid withdrawal in morphine-tolerant mice [131-134]. Co-treatment with CB2R agonist JWH015 or LY2828360 blocks acquisition of morphine CPP [131, 135], without producing reward or aversion when administered alone [131]. JWH015 reduces morphine-induced dopamine release in the NAc shell, which may explain the inhibition of morphine reward by this CB2R agonist [135]. This preliminary research supports future investigations into CB2R agonists for the treatment of opiate withdrawal and reward is warranted, and the mechanisms by which this occurs.

**Conclusions**

Here we have summarised the therapeutic potential of cannabinoid-based drugs for managing opioid withdrawal, dependence and addiction-like behaviour. Interactions between the endogenous opioid and endocannabinoid systems present a novel therapeutic target for treating opioid addiction. In particular, CBD, FAAH and MAGL inhibitors, as well as CB1R antagonists show potential for treating opiate withdrawal, reward and relapse-like behaviour. Investigations into the mechanisms by which these ligands reduce opiate reward and opiate-seeking behaviour has been limited, but to date include modulation of 5-HT1AR, DαR, GluR1 and CB1R (relevant to CBD), CB1R and PPARα (relevant to FAAH and MAGL inhibitors), and ERK-CREB-BDNF (relevant to CB1R antagonists). While the literature suggests that CB1R agonists can reduce opiate withdrawal in rodents, CB1R agonists can also enhance opiate reward and precipitate opiate relapse-like behaviour, making these agonists unsuitable in their current form as therapeutic options for opiate addiction.
Implications and Future Directions

Several cannabinoid ligands show therapeutic promise in animal models for reducing opiate abuse liability and addiction-like behaviour. This presents a significant array of compounds with treatment potential, and may start to change the perception of cannabinoids from party drug to potential medicine. However, several ligands have significant side effects which can limit their therapeutic application (e.g. hallucinogenic effects of THC, suicidal ideation and anxiety following SR141716A treatment). Also, cannabis use can exacerbate or increase risk for the development of other mental health conditions (e.g. schizophrenia) [136], and it is possible that other cannabinoid compounds may also have similar effects, potentially restricting the use of some cannabinoids in clinical settings.

Nonetheless, research to investigate the mechanisms of action by which these ligands exert anti-addiction-like effects may provide more refined and targeted compounds for opiate abuse treatment. For example, investigations into the mechanisms by which CB1R agonists reduce opiate withdrawal may provide new therapeutic opportunities for ligands which can limit withdrawal, without enhancing opiate reward. Indeed, interest in cannabinoid ligands as a potential treatment for opiate abuse is evidenced by the recent proliferation of research into CB1R antagonists, as well as cannabinoid enzyme inhibitors. Furthermore, combinations of some cannabinoid compounds (e.g. FAAH and MAGL inhibitors) may prove more effective than these compounds individually, again providing a new host of potential treatment options. While investigations into CB1R antagonists other than SR141716A and cannabinoid enzyme inhibitors are fairly recent, and the mechanism of action of these drugs is presently unclear, this is an exciting and novel avenue of research. Finally, the potential of CB2R modulators to reduce opiate abuse liability has received very little attention so far, but considering CB2R can modulate reward behaviours for other abused drugs (e.g. ethanol and cocaine [137, 138]), investigations into how CB2R modulates opiate addiction-relevant behaviours are also warranted.

Declarations

Acknowledgements

We would like to thank Jennifer Collins for proof reading the manuscript.

Funding

RC is funded by the Ainsworth Medical Research Innovation Fund and the Rebecca Cooper Medical Research Foundation.

Conflict of Interest Declaration

RC is an editor for Neuroanatomy and Behaviour and a member of the committee of management of Episteme Health.

Editorial Notes

History

Received: 2020–09–28
Revisions Requested: 2020–12–13
Revised: 2021–04–09
Accepted: 2021–05–14
Published: 2021–06–12

References


40. Gonzalez S, Schmid PC, Fernandez-Ruiz J, Krebsbach R,


